☆ 4.6 Article

ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update

JOURNAL OF CROHNS & COLITIS (2017)

Journal

JOURNAL OF CROHNS & COLITIS

Volume 11, Issue 1, Pages 26-34

Publisher

OXFORD UNIV PRESS

DOI: 10.1093/ecco-jcc/jjw198

Keywords

-

Categories

Gastroenterology & Hepatology

Funding

AbbVie
MSD
Pfizer/Hospira
Takeda
Boehringer-Ingelheim
Chiesi
Falk
Ferring
Janssen
Mitsubishi Tanabe
Tillotts
Zeria

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Gastroenterology & Hepatology

Definitions of Histological Abnormalities in Inflammatory Bowel Disease: an ECCO Position Paper

Roger Feakins, Paula Borralho Nunes, Ann Driessen, Ilyssa O. Gordon, Nina Zidar, Pamela Baldin, Britt Christensen, Silvio Danese, Naoimh Herlihy, Marietta Iacucci, Maurice B. Loughrey, Fernando Magro, Aart Mookhoek, Magali Svrcek, Francesca Rosini

Summary: Histological assessment is important in the management and study of inflammatory bowel disease (IBD), but definitions and recognition of abnormal histological features are often inconsistent. The European Crohn's and Colitis Organisation (ECCO) formed an expert panel to explore and improve the quality of diagnosis by producing a series of consensus statements on histological features in IBD.

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Review Gastroenterology & Hepatology

Biosimilars in Inflammatory Bowel Disease

Anna M. Buchner, Yecheskel Schneider, Gary R. Lichtenstein

Summary: Biological therapy targeting tumor necrosis factor-alpha has become crucial in treating patients with inflammatory bowel disease, but high costs limit accessibility. Biosimilars offer the potential to reduce expenditures and increase availability, providing more options for patients.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

ECCO Topical Review: Refractory Inflammatory Bowel Disease

Tim Raine, Bram Verstockt, Uri Kopylov, Konstantinos Karmiris, Rimma Goldberg, Raja Atreya, Johan Burisch, John Burke, Pierre Ellul, Charlotte Hedin, Stefan D. Holubar, Konstantinos Katsanos, Triana Lobaton, Carsten Schmidt, Garret Cullen

Summary: Inflammatory bowel disease is a chronic condition with varying degrees of severity and activity. Some patients do not respond to approved treatments, requiring a systematic approach involving medical options, surgery, and support services. This review aims to guide clinicians by providing an accurate summary of available evidence for different strategies.

JOURNAL OF CROHNS & COLITIS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicentre Case Series

Brigida Barberio, Edoardo Savarino, Bram Verstockt, Mathurin Fumery, Daniela Pugliese, Lorenzo Bertani, Andrea Buda, Gabriele Dragoni, Idan Goren, Ido Laish, Antonino Spinelli, Niels Teich, Marie Truyens, Pierre Ellul

Summary: This is the largest case series of patients with IBD and HCCS to date, and Lynch syndrome was the most common diagnosis of HCCS associated with IBD. Despite endoscopic surveillance, these IBD patients had a high rate of malignant tumor development and surgical intervention.

JOURNAL OF CROHNS & COLITIS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series

Stefano Festa, Giulia Zerboni, Lauranne A. A. P. Derikx, Davide Giuseppe Ribaldone, Gabriele Dragoni, Christianne Buskens, Els Nieveen van Dijkum, Daniela Pugliese, Francesco Panzuto, Iwona Krela-Kazmierczak, Hilla Reiss Mintz, Ariella Bar-Gil Shitrit, Maria Chaparro, Javier P. Gisbert, Uri Kopylov, Niels Teich, Elez Vainer, Iris Nagtegaal, Frank Hoentjen, Maria Jose Garcia, Rafal Filip, Kalliopi Foteinogiannopoulou, Ioannis E. Koutroubakis, Marjorie Argollo, Roy L. J. van Wanrooij, Hendrik Laja, Triana Lobaton, Marie Truyens, Tamas Molnar, Edoardo Savarino, Annalisa Aratari, Claudio Papi, Idan Goren

Summary: In patients with GEP-NEN and IBD, the prognosis seems favorable and the therapies related to IBD are probably independent of NEN progression. Incidental NEN diagnosis may be associated with an earlier NEN stage.

JOURNAL OF CROHNS & COLITIS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Primary Hypogammaglobulinaemia with Inflammatory Bowel Disease-Like Features: An ECCO CONFER Multicentre Case Series

Ahmad Albshesh, Piotr Eder, Davide Giuseppe Ribaldone, Bas Oldenburg, Nanne K. de Boer, Gerassimos J. Mantzaris, Edoardo Vincenzo Savarino, Gabriele Dragoni, Roni Weisshof, Marie Truyens, Stefano Festa, Michel H. Maillard, Lena Capirchio, Rafal Filip, Eirini Theodoraki, Uri Kopylov

Summary: This case series study describes IBD-like features in patients with hypogammaglobulinaemia, which were mainly diagnosed after hypogammaglobulinaemia and successfully relieved through appropriate treatment.

JOURNAL OF CROHNS & COLITIS (2022)

Add to Collection

Review Genetics & Heredity

Genetic and Epigenetic Etiology of Inflammatory Bowel Disease: An Update

Sara Jarmakiewicz-Czaja, Magdalena Zielinska, Aneta Sokal, Rafal Filip

Summary: This review examines the genetic factors associated with inflammatory bowel disease (IBD), including disease predisposition and pharmacogenetics.

GENES (2022)

Add to Collection

Review Gastroenterology & Hepatology

The Sincerest Form of Flattery? Biosimilars in Inflammatory Bowel Disease

Seema A. Patil, Shubha Bhat, Jimmy K. Limdi, Francis A. Farraye, Raymond K. Cross

Summary: Biosimilar medications can significantly reduce treatment costs for patients with inflammatory bowel disease. Observational studies have demonstrated similar efficacy and safety between biosimilars and biologic reference products. Shared decision-making is crucial for the successful implementation of these agents.

INFLAMMATORY BOWEL DISEASES (2022)

Add to Collection

Review Pharmacology & Pharmacy

Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence

Valeria Dipasquale, Giuseppe Cicala, Edoardo Spina, Claudio Romano

Summary: This study reviewed the use of biosimilars in pediatric inflammatory bowel disease (IBD) patients and found that the effectiveness of CT-P13, a biosimilar of anti-TNF-alpha, was similar to that of the originator drug IFX in terms of clinical response and remission rates.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Development of a Core Outcome Set for Real-world Data in Inflammatory Bowel Disease: A European Crohn's and Colitis Organisation [ECCO] Position Paper

Jurij Hanzel, Peter Bossuyt, Valerie Pittet, Mark Samaan, Monika Tripathi, Wladyslawa Czuber-Dochan, Johan Burisch, Salvatore Leone, Roberto Saldana, Filip Baert, Uri Kopylov, Susanna Jaghult, Michel Adamina, Naila Arebi, Krisztina Gecse

Summary: This study aimed to develop a core outcome set for real-world studies in adult patients with inflammatory bowel disease (IBD). Candidate outcomes and outcome measures were identified through a systematic review and a modified Delphi consensus process. The international panel agreed on the final core outcome set, which will facilitate the synthesis and generation of real-world evidence.

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Article Gastroenterology & Hepatology

Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study]

Maria Chaparro, Lumir Kunovsky, Mariam Aguas, Moran Livne, Pauline Riviere, Ariella Bar-Gil Shitrit, Par Myrelid, Maite Arroyo, Manuel Barreiro-de Acosta, Michelle Bautista, Livia Biancone, Irit Avni Biron, Trine Boysen, Daniel Carpio, Beatriz Castro, Gabriele Dragoni, Pierre Ellul, Stefan D. Holubar, Miguel Angel de Jorge, Eduardo Leo, Noemi Mancenido, Annick Moens, Tamas Molnar, Patricia Ramirez de la Piscina, Petr Ricanek, Ladislava Sebkova, Laura Sempere, Niels Teich, Javier P. Gisbert, Mette Julsgaard

Summary: Evaluation of pregnancies and offspring after inflammatory bowel disease (IBD) surgery during pregnancy is important. Surgical management should involve a multidisciplinary team.

JOURNAL OF CROHNS & COLITIS (2022)

Add to Collection

Article Gastroenterology & Hepatology

The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update

Patrick F. van Rheenen, Marina Aloi, Amit Assa, Jiri Bronsky, Johanna C. Escher, Ulrika L. Fagerberg, Marco Gasparetto, Konstantinos Gerasimidis, Anne Griffiths, Paul Henderson, Sibylle Koletzko, Kaija-Leena Kolho, Arie Levine, Johan van Limbergen, Francisco Javier Martin de Carpi, Victor Manuel Navas-Lopez, Salvatore Oliva, Lissy de Ridder, Richard K. Russell, Dror Shouval, Antonino Spinelli, Dan Turner, David Wilson, Eytan Wine, Frank M. Ruemmele

Summary: This study emphasizes the importance of early assessment of high-risk patients with Crohn's disease to reduce intestinal damage, and recommends upfront anti-TNF agents in combination with an immunomodulator for patients with perianal disease, stricturing or penetrating behavior, or severe growth retardation. Therapeutic drug monitoring is preferred over empirically escalating anti-TNF dose or switching therapies. For low-risk luminal CD patients, induction with exclusive enteral nutrition or corticosteroids, and maintenance therapy with immunomodulators are recommended.

JOURNAL OF CROHNS & COLITIS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Autoimmune Pancreatitis in Patients with Inflammatory Bowel Disease: A Real-World Multicentre Collaborative ECCO CONFER Study

Piotr Eder, Bram Verstock, Emma Culver, Gabriele Dragoni, Lea Isabell Kredel, Joanna Wypych, Ana Garcia Garcia de Paredes, Magdalena Kaniewska, Haim Leibovitzh, Triana Lobaton, Marie Truyens, Grzegorz Oracz, Davide Giuseppe Ribaldone, Teresa Starzynska, Abdenor Badaoui, Jean-Francois Rahier, Cristina Bezzio, Peter Bossuyt, Katherine Falloon, Daniela Pugliese, Catherine Frakes Vozzo, Tine Jess, Lone Larsen, Soren Schou Olensen, Partha Pal, Maria Chaparro, Dikla Dror, Pierre Ellul, Iga Gromny, Maria Janiak, Katarzyna Maciejewska, Noam Peleg, Ariella Bar-Gil Shitrit, Lukasz Szwed, Renata Talar-Wojnarowska, Yifat Snir, Roni Weisshof, Eran Zittan, Izabela Miechowicz, Idan Goren

Summary: This study investigated the long-term outcomes of autoimmune pancreatitis (AIP) and inflammatory bowel disease (IBD) in patients with coexisting AIP-IBD, as well as the predictors of complicated AIP course. The majority of patients had type 2 AIP and colonic IBD, and the AIP course was relatively benign with favorable prognosis, but a quarter of the patients developed pancreatic complications. Age, family history, and CD were identified as potential predictors of uncomplicated AIP course.

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Article Plant Sciences

A recent update on the use of Chinese medicine in the treatment of inflammatory bowel disease

Lin Yang, Hua Luo, Dechao Tan, Siyuan Zhang, Zhangfeng Zhong, Shengpeng Wang, Chi Teng Vong, Yitao Wang

Summary: This review provides a summary of recent studies on the effects and mechanisms of Chinese medicine in treating IBD. It highlights the advantages of Chinese medicine in managing IBD and serves as a reference for further evaluation and exploration of its potential in treating IBD with classical multi-herbal Chinese medicine.

PHYTOMEDICINE (2021)

Add to Collection

Article Pharmacology & Pharmacy

An update on the safety of long-term vedolizumab use in inflammatory bowel disease

Sailish Honap, Patrick Netter, Silvio Danese, Laurent Peyrin-Biroulet

Summary: This article assesses the safety profile of Vedolizumab in the treatment of inflammatory bowel disease, including long-term overall safety and safety in special populations. The results show that Vedolizumab is an effective and safe treatment, with no unexpected long-term safety signals identified. Safety data in pregnant women, children, elderly patients, patients undergoing surgery, and patients with a prior history of cancer are also reassuring.

EXPERT OPINION ON DRUG SAFETY (2023)

Add to Collection

Article Gastroenterology & Hepatology

Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study

Gaetano Bergamaschi, Fabiana Castiglione, Renata D'Inca, Marco Astegiano, Walter Fries, Monica Milla, Carolina Ciacci, Fernando Rizzello, Simone Saibeni, Rachele Ciccocioppo, Ambrogio Orlando, Fabrizio Bossa, Mariabeatrice Principi, Piero Vernia, Chiara Ricci, Maria L. Scribano, Giorgia Bodini, Dario Mazzucco, Gabrio Bassotti, Gabriele Riegler, Andrea Buda, Matteo Neri, Flavio Caprioli, Fabio Monica, Aldo Manca, Erica Villa, Gionata Fiorino, Michele Comberlato, Nicola Aronico, Cristina Della Corte, Roberta Caccaro, Paolo Gionchetti, Paolo Giuffrida, Paola Iovino, Marco Lenti, Caterina Mengoli, Lucienne Pellegrini, Alberto Pieraccini, Davide Ribaldone, Anna Testa, Cristina Ubezio, Anna Viola, Maurizio Vecchi, Catherine Klersy, Antonio Di Sabatino

Summary: The prevalence of anemia in Italian IBD patients is lower than previously reported, with the majority being caused by iron deficiency and leading to fatigue and decreased quality of life. However, a large proportion of patients with iron and/or vitamin deficiencies remain untreated.

INFLAMMATORY BOWEL DISEASES (2023)

Add to Collection

Article Gastroenterology & Hepatology

Early Biological Therapy in Operated Crohn's Disease Patients Is Associated With a Lower Rate of Endoscopic Recurrence and Improved Long-term Outcomes: A Single-center Experience

Ferdinando D'Amico, Olga Tasopoulou, Gionata Fiorino, Alessandra Zilli, Federica Furfaro, Mariangela Allocca, Pierpaolo Sileri, Antonino Spinelli, Laurent Peyrin-Biroulet, Silvio Danese

Summary: This study aimed to investigate the impact of postoperative biological therapy on the incidence of endoscopic recurrence and long-term outcomes in Crohn's disease patients. The results showed that early treatment with biologics decreased the rates of endoscopic recurrence and hospitalization/surgery.

INFLAMMATORY BOWEL DISEASES (2023)

Add to Collection

Article Gastroenterology & Hepatology

IBD Flare in the COVID-19 Pandemic: Therapy Discontinuation Is to Blame

Cristina Bezzio, Gionata Fiorino, Davide G. Ribaldone, Alessandro Armuzzi, Simone Saibeni

Summary: This study investigated the impact of severe acute respiratory syndrome coronavirus 2 infection on inflammatory bowel disease course and found that therapy discontinuation is a risk factor for disease flare.

INFLAMMATORY BOWEL DISEASES (2023)

Add to Collection

Article Gastroenterology & Hepatology

Long-term Colectomy Rates of Ulcerative Colitis over 40 Years of Different Therapeutic Eras-Results from a Western Hungarian Population-based Inception Cohort Between 1977 and 2020

Panu Wetwittayakhlang, Lorant Gonczi, Laszlo Lakatos, Zsuzsanna Kurti, Petra Golovics, Tunde Pandur, Gyula David, Zsuzsanna Erdelyi, Istvan Szita, Peter L. Lakatos

Summary: This study aimed to assess the colectomy rates of ulcerative colitis (UC) patients in Veszprem Province, Hungary over 40 years. The results showed no significant differences in colectomy rates among different therapeutic eras, despite increasing use of immunomodulators and biologic therapies.

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Review Medicine, Research & Experimental

Dose Escalation Patterns of Advanced Therapies in Crohn's Disease and Ulcerative Colitis: A Systematic Literature Review

Remo Panaccione, Wan-Ju Lee, Ryan Clark, Kristina Kligys, Rhiannon I. Campden, Stacy Grieve, Tim Raine

Summary: This study aimed to identify and characterize the dosing escalation patterns of advanced therapies in Crohn's disease (CD) and ulcerative colitis (UC). The study found that most studies aligned with regulatory recommendations, but there were also some studies indicating more diverse or aggressive dose escalation.

ADVANCES IN THERAPY (2023)

Add to Collection

Review Gastroenterology & Hepatology

Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials

Mohammad Shehab, Fatema Alrashed, Afrah Alkazemi, Peter L. Lakatos, Talat Bessissow

Summary: The aim of this study was to estimate the risk of major adverse cardiovascular events (MACE) in adult patients with inflammatory bowel disease (IBD) treated with biologic therapies and small molecules. The results showed that the risk of MACE was not higher than placebo in patients receiving biologic or small molecule therapies during induction and maintenance phases of randomized controlled trials (RCTs).

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2023)

Add to Collection

Review Medicine, General & Internal

The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer

Panu Wetwittayakhlang, Paraskevi Tselekouni, Reem Al-Jabri, Talat Bessissow, Peter L. Lakatos

Summary: Patients with inflammatory bowel disease (IBD) have an increased risk of cancer due to chronic inflammation and long-term use of immunosuppressive therapy. The prevalence of cancer in IBD patients is increasing, requiring concern about the impact of IBD therapy on cancer risk and survival. Managing IBD patients with cancer is challenging as guidelines are based on expert consensus and evidence is limited.

JOURNAL OF CLINICAL MEDICINE (2023)

Add to Collection

Article Gastroenterology & Hepatology

The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission

Johan Burisch, Mirabella Zhao, Selwyn Odes, Peter De Cruz, Severine Vermeire, Charles N. Bernstein, Gilaad G. Kaplan, Dana Duricova, Dan Greenberg, Hans O. Melberg, Mamoru Watanabe, Hyeong Sik Ahn, Laura Targownik, Valerie E. H. Pittet, Vito Annese, K. T. Park, Konstantinos H. Katsanos, Marte L. Hoivik, Zeljko Krznaric, Maria Chaparro, Edward V. Loftus, Peter L. Lakatos, Javier P. Gisbert, Willem Bemelman, Bjorn Moum, Richard B. Gearry, Michael D. Kappelman, Ailsa Hart, Marieke J. Pierik, Jane M. Andrews, Siew C. Ng, Renata D'Inca, Pia Munkholm

Summary: The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase worldwide due to the steady increase in prevalence, the chronic nature of the diseases, expensive treatments, intensive monitoring, and their impact on productivity. This Commission urges evaluation of cost increases against improved disease management and the need for data interoperability and big data approaches to assess effectiveness and cost-effectiveness. International collaborations and novel care models should be sought to enhance education and training for clinicians, patients, and policy makers.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2023)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Frequent Early Nocebo Complaints but Maintained Clinical Efficacy, Biomarker and Therapeutic drug levels following mandatory Biosimilar Switch in Patients with Inflammatory Bowel disease: Preliminary data from a Prospective Observational Cohort Study

P. Wetwittayakhlang, K. Karkout, P. Tselekouni, R. Aljabri, T. Bessissow, W. Afif, G. Wild, A. Bitton, P. L. Lakatos

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

The Burden of Colorectal Cancer in Patients with Ulcerative Colitis - Incidence and Risk factors from a Population-based Inception Cohort from Veszprem county, Western Hungary, from 1977-2020

P. Wetwittayakhlang, P. Golovics, L. Gonczi, A. Khoury, Z. Kurti, T. Pandur, G. David, Z. Erdelyi, I. Szita, L. Lakatos, P. L. Lakatos

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Time Trends of Environmental and Socioeconomical Factors in Patients with Inflammatory Bowel Disease over 40-year of Different Therapeutic Eras; results from a Population-based Cohort from Western Hungarian between 1977-2020, The Hygiene hypothesis revisited

P. Wetwittayakhlang, L. Gonczi, L. Lakatos, P. Golovics, T. Pandur, G. David, Z. Erdelyi, I. Szita, P. L. Lakatos

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Long-term Colectomy rates of Ulcerative Colitis over 40-year of Different Therapeutic eras - Results from a Western Hungarian Population-based Inception Cohort between 1977-2020

P. L. Lakatos, L. Gonczi, L. Lakatos, P. A. Golovics, T. Pandur, G. David, Z. Erdelyi, I. Szita

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Real life efficacy of tofacitinib in different situation in ulcerative colitis: a retrospective worldwide multicentre collaborative study

T. Resal, P. Bacsur, R. Bor, A. Balint, K. Katsanos, G. Michalopoylos, D. G. Ribaldone, M. Attauabi, Z. Mirabella, H. Yanai, C. Bezzio, F. Castiglione, A. Bar-Gil Shitrit, D. Pugliese, P. L. Lakatos, E. Savarino, M. Lukas, M. Franko, E. Chashkova, P. Molander, S. Nancey, L. Bannon, Z. Krznaric, R. Filip, T. Szamosi, K. Kastylova, P. Sarlos, H. Ami-Barak, A. Rispo, J. Limdi, A. Kagramanova, Z. Szepes, K. Farkas, T. Molnar

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Endoscopic and clinical outcomes of upadacitinib in patients with moderate to severe Crohn's disease by baseline disease severity

B. Siegmund, K. Patel, E. A. Torres, P. L. Lakatos, J. Seidelin, M. Fleisher, S. Ford, V. Remple, A. P. Lacerda, S. Anyanwu, A. Garrison, J. Panes

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Article Gastroenterology & Hepatology

Nonalcoholic Fatty Liver Disease Increases Cardiovascular Risk in Inflammatory Bowel Diseases

Dana Kablawi, Faisal Aljohani, Chiara Saroli Palumbo, Sophie Restellini, Alain Bitton, Gary Wild, Waqqas Afif, Peter L. Lakatos, Talat Bessissow, Giada Sebastiani

Summary: This study found that nonalcoholic fatty liver disease (NAFLD) is more frequent in patients with inflammatory bowel disease (IBD) and is strongly associated with cardiovascular risk, particularly in patients with longer IBD duration and ulcerative colitis.

CROHNS & COLITIS 360 (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.